NEW YORK – M2Gen said Friday that it has expanded its partnership with Discovery Life Sciences to provide pipeline analysis for tumor-normal and tumor-only somatic mutation identification for whole-exome sequences, as well as gene expression and fusion detection from tumor RNA sequencing.